Therapeutic Management of Congestive Heart Failure (CHF) in Dogs

Disease Staging (ACVIM / Modified ACC-AHA)

Stage A — No Treatment

Stage B1 — No Cardiac Drugs

• No pharmacological therapy is currently recommended.
• Regular recheck examinations (every 12 months).
• Chest radiographs and echocardiography to monitor for progression.

Stage B2 — Pre-clinical with Cardiac Enlargement

Key Drug: Pimobendan (VETMEDIN)

• Dose: 0.25–0.30 mg/kg PO q12h, given on an empty stomach (~1 hour before feeding)
• Mechanism: Calcium sensitizer + phosphodiesterase III inhibitor → positive inotrope + vasodilator ("inodilator")
• Evidence: The landmark EPIC trial (Boswood et al., 2016) showed pimobendan delayed onset of CHF by a median of 15 months in Stage B2 dogs
• Class I recommendation (ACVIM 2019)

ACE inhibitors are NOT recommended for Stage B2 unless the dog has concurrent hypertension or significant proteinuria. This was a key change from the 2009 guidelines.

Stage C — Active / Prior CHF

1. Acute (Hospital-Based) Emergency Management

Once the respiratory rate is < 30 breaths/minute (resting), transition to chronic oral therapy.

2. Chronic (Home-Based) Maintenance Therapy

A. Furosemide (Loop Diuretic)

• Dose: 1–2 mg/kg PO q12h (titrate to lowest effective dose)
• Monitor renal values (BUN, creatinine) and electrolytes (Na⁺, K⁺) every 3–6 months
• Dose escalation is expected as disease progresses

B. Pimobendan

• Dose: 0.25–0.30 mg/kg PO q12h (empty stomach)
• Continue from acute phase; do NOT discontinue
• Off-label 3× daily dosing (0.3 mg/kg q8h) may be used in refractory cases

C. ACE Inhibitor (ACEI)

• Enalapril: 0.5 mg/kg PO q12h
• Benazepril: 0.5 mg/kg PO q12h or q24h
• Mechanism: Inhibits angiotensin-converting enzyme → reduces angiotensin II and aldosterone → reduces preload and afterload, mitigates RAAS activation
• Class I recommendation for chronic Stage C
• Monitor renal function and blood pressure; reduce dose if azotemia develops

D. Spironolactone (Aldosterone Antagonist)

• Dose: 1–2 mg/kg PO q12h or q24h
• Mechanism: Blocks aldosterone receptors in renal collecting duct → K⁺-sparing diuretic + antifibrotic cardiac effects
• BESST study (2021): Spironolactone + benazepril added to furosemide significantly reduced/delayed CHF recurrence in stabilized Stage C MMVD dogs vs. placebo + benazepril
• Class IIa recommendation in ACVIM 2019; evidence has strengthened since
• Monitor potassium (hyperkalemia risk, especially when combined with ACEI)

Additional Adjunctive Therapies (Stage C)

Dietary Management

• Mild sodium restriction (avoid high-sodium treats/foods; do NOT use severe sodium restriction as it activates RAAS)
• Maintain lean body condition; cachexia is a poor prognostic sign
• Ensure adequate protein intake
• Omega-3 fatty acids (EPA + DHA): may reduce cardiac cachexia and have mild anti-inflammatory effects; no consensus dosing, but ~40 mg/kg/day EPA+DHA is commonly cited

Digoxin

• Rarely used now but indicated for:
  • Atrial fibrillation rate control (Dobermans with DCM + AF)
  • As adjunctive positive inotrope if pimobendan not available
• Dose: 0.005–0.008 mg/kg PO q12h; monitor serum digoxin levels (therapeutic range: 0.8–2.0 ng/mL; measure 8–10 hours post-dose)
• Narrow therapeutic index; toxicity causes anorexia, vomiting, arrhythmias

Antiarrhythmic Drugs

• Atrial fibrillation (common in DCM and advanced MMVD):
  • Diltiazem 0.5–2 mg/kg PO q8h or sustained-release formulations
  • Digoxin (as above) — often combined with diltiazem for rate control
  • Target resting heart rate < 140 bpm
• Ventricular arrhythmias (Dobermans, Boxers with DCM or ARVC):
  • Sotalol 1–2.5 mg/kg PO q12h
  • Mexiletine 4–8 mg/kg PO q8h (often combined with sotalol)
  • Amiodarone: reserved for refractory cases; hepatotoxicity risk

Stage D — Refractory / End-Stage CHF

Disease-Specific Considerations

Myxomatous Mitral Valve Disease (MMVD)

• Most common in small/toy breeds (Cavalier King Charles Spaniel, Dachshund, Maltese, Chihuahua)
• Left-sided CHF dominates (pulmonary edema)
• Standard staging and treatment as outlined above
• Mitral valve repair surgery: Increasingly available at specialized centers; best outcomes before onset of CHF (Stage B2); strong recommendation if performed at experienced centers

Dilated Cardiomyopathy (DCM)

• Large/giant breeds: Doberman Pinscher, Great Dane, Irish Wolfhound, Boxer
• Systolic dysfunction (reduced contractility) is the primary defect
• Pimobendan is critical — strong evidence in Dobermans (PROTECT study)
• DCM in dogs fed grain-free/high-legume diets: consider taurine supplementation (500 mg/dog PO q12h) and dietary change
• Arrhythmias (atrial fibrillation, VPCs) are more common and often require concurrent antiarrhythmic therapy

Pericardial Effusion

• Acute cardiac tamponade: pericardiocentesis is life-saving
• Recurrent effusion (hemangiosarcoma, idiopathic): pericardiectomy considered

Monitoring Parameters

Summary of Drug Classes, Doses, and Mechanisms

Key References

• ACVIM Consensus Guidelines 2019 (Keene et al.) — MMVD in Dogs — PMID 30974015 — the primary evidence-based guideline
• EPIC Trial (Boswood et al., 2016): Pimobendan in Stage B2 MMVD
• PROTECT Study (Summerfield et al., 2012): Pimobendan in Doberman DCM
• BESST Study (2021): Spironolactone + benazepril in stabilized Stage C MMVD

Note: The library does not contain veterinary-specific textbooks. This answer is based on the ACVIM 2019 consensus guidelines, BESST/EPIC/PROTECT clinical trial data, and current veterinary cardiology practice. Always verify doses against current formularies (Plumb's Veterinary Drug Handbook) and adjust for individual patient renal function and clinical response.